Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system.
It is a $150B healthcare company. Revenue grew 20.7% over the last year, and it keeps 28¢ of every dollar of sales as profit. It trades at 47.7× earnings — near the lowest of its own history.
- Website
- intuitive.com
- Location
- Sunnyvale, CA
- Employees
- 17 021
- Sector
- Healthcare
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Strong growth, profitability, quality and moat; Valuation lags behind.
Valuation35
- P/E vs own history7th pct · 25/25
- FCF yield2.2% · 5/25
- P/S13.6x · 5/25
- EV/EBITDA40.7x · 0/25
Growth90
- Revenue CAGR15.2% · 20/25
- Net income CAGR13.8% · 20/25
- EPS CAGR ~5Y21.8% · 25/25
- Fwd implied growth39.2% · 25/25
Profitability90
- ROIC24.0% · 20/25
- ROE17.8% · 20/25
- Net margin28.4% · 25/25
- Operating margin31.3% · 25/25
Health50
- Altman Zn/a · 0/25
- Current ratio4.96 · 25/25
- Interest coverageno interest expense · 25/25
- Net cash / debtn/a · 0/25
Quality85
- Piotroski F6/9 · 15/25
- Beneish M-2.31 · 20/25
- FCF conversion103% · 25/25
- Margin stabilityσ 3.8% · 25/25
Moat100
- ROIC >12% years10/10 yrs · 25/25
- Median gross margin68.4% · 25/25
- FCF-positive years10/10 yrs · 25/25
- Worst-year net marginworst 21.1% · 25/25
Experience
The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.
- FY2025FinancialRevenue crossed $10B$10.1B for the year
- FY2025FinancialBest year on record$2.86B net income
- 2024MilestoneIntuitive Surgical first appeared on the Fortune 500 in 2024 at number 497
- FY2016FinancialProfitable every year on record10 consecutive profitable years in our data
- FY2016FinancialRevenue already above $1B$2.70B in first reported year
- FY2016FinancialPositive free cash flow every year since10-year streak
- 2000IPOThe company raised $46 million in an initial public offering in 2000
- 1995ProductMoll was introduced to John Freund who had recently left Acuson Corporation
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
- High gross margin (66.7%)
- Strongly profitable — 28.4% net margin
- Revenue growing 20.7% year over year
- Strong cash conversion — FCF is 29.2% of revenue
- High returns on invested capital (ROIC 24.0%)
Watch-outs
Nothing stands out as a concern in the available data.
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year ago+20.7% YoY
- Profitable — makes more than it spends$3.14B TTM
- Profit growing — earnings are higher than last year+29.2% YoY
- Generates cash — cash left after running and investing$3.22B TTM
- Debt under control — could handle its obligationscurrent ratio 4.96
- Established company — not a micro-cap — lower blow-up risk$150B market cap
- Not printing shares — share count not ballooning — you keep your slice+0.5% shares over ~5y
- Proven track record — years of profitability behind it10/10 profitable years
- Financially stable — balance sheet not near distresshealth score 50/100
- Pays a dividend — returns cash to shareholdersno data
- Valuation not extreme — price not wildly above earningsP/E 47.7
Peer comparisonIntuitive Surgical Inc. vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| ISRG this company | $149.7B | 47.7 | +20.7% | 28.4% | Mixed |
| LLY Eli Lilly & Co. | $1.0T | 41.6 | +49.6% | 33.5% | Solid |
| JNJ Johnson & Johnson | $630.9B | 29.9 | +8.1% | 21.5% | Mixed |
| ABBV Abbvie Inc. | $488.5B | 77.4 | +10.4% | 9.8% | Mixed |
| MRK Merck & Co., Inc. | $361.0B | 113.2 | +4.6% | 4.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $340.7B | 24.1 | +6.5% | 3.1% | Mixed |
| NVS Novartis AG | $273.2B | 20.3 | +9.6% | 24.7% | Solid |
Head-to-head: ISRG vs LLY · ISRG vs JNJ · ISRG vs ABBV
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2016–FY2025. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/ISRG
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of ISRG on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $423.80 · market cap $150B.